Dr. Lee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
# Dana-Far
Boston, MA 02215Phone+1 617-632-6094Fax+1 617-632-3479
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2020
Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
University of Pittsburgh School of MedicineClass of 2014
Certifications & Licensure
MA State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 2 citationsAtaxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study).Elisa Fontana, Ezra Rosen, Elizabeth K Lee, Martin Højgaard, Niharika B Mettu
Journal of the National Cancer Institute. 2024-09-01 - Uterine serous carcinoma and uterine carcinosarcoma: molecular features, clinical advances, and emerging therapies.Elizabeth K Lee, Joyce F Liu
Clinical Advances in Hematology & Oncology. 2024-08-07 - Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.Panagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, Joyce F Liu, Hannah Sawyer
Gynecologic Oncology Reports. 2024-04-01
Journal Articles
- POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA, Gynecologic Oncology Reports, 5/2019
Press Mentions
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialSeptember 15th, 2024- Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
